Generic placeholder image

Current Hypertension Reviews

Author(s): Zinhle P. Mlambo*, Olive P. Khaliq, Jagidesa Moodley and Thajasvarie Naicker

DOI: 10.2174/1573402119666221130164622

DownloadDownload PDF Flyer Cite As
Circulatory and Placental Expression of Soluble Fms-like Tyrosine Kinase- 1 and Placental Growth Factor in HIV-infected Preeclampsia

Page: [27 - 33] Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

An imbalance between angiogenic and anti-angiogenic factors plays a fundamental role in the pathogenesis of preeclampsia (PE). Studies have shown a dysregulation of sFlt-1 and placental growth factor (PlGF) in PE. However, there are differing reports on the levels of these pro-/antiangiogenic factors in HIV-infected preeclamptic and normotensive pregnancies, possibly due to highly active antiretroviral therapy (HAART) and its immune reconstitution effect. The study aimed to investigate the effect of hypertension and ARVs on circulating and placental pro- and antiangiogenic factors in HIV-infected PE. The level of sFlt-1 expression is elevated in PE compared to normal pregnancies. PlGF was altered by placental dysfunction. Antiretroviral therapy does not impact the angiogenic shift in PE development. The angiogenic imbalance evident in the circulatory system by higher sFlt-1 compared to PlGF levels is replicated in the placenta by reduced expression of PlGF receptors in comparison to sFlt-1 receptors. However, there is a lack of data that explore the relationship between HAART and anti-angiogenic factors in the placenta and the circulation of PE comorbid with HIV infection.

Graphical Abstract

[1]
Felmeden D, Blann AD, Lip GYH. Angiogenesis: Basic pathophysiology and implications for disease. Eur Heart J 2003; 24(7): 586-603.
[http://dx.doi.org/10.1016/S0195-668X(02)00635-8] [PMID: 12657217]
[2]
Padayachee S, Moodley J, Naicker T. A review of angiogenic imbalance in HIV-infected hypertensive disorders of pregnancy. Curr Hypertens Rep 2019; 21(9): 69.
[http://dx.doi.org/10.1007/s11906-019-0970-7] [PMID: 31342170]
[3]
Esemu LF, Yuosembom EK, Fang R, et al. Impact of HIV-1 infection on the IGF-1 axis and angiogenic factors in pregnant Cameroonian women receiving antiretroviral therapy. PLoS One 2019; 14(5): e0215825.
[http://dx.doi.org/10.1371/journal.pone.0215825] [PMID: 31042729]
[4]
Pratt A, Da Silva Costa F, Borg AJ, Kalionis B, Keogh R, Murthi P. Placenta-derived angiogenic proteins and their contribution to the pathogenesis of preeclampsia. Angiogenesis 2015; 18(2): 115-23.
[http://dx.doi.org/10.1007/s10456-014-9452-3] [PMID: 25433512]
[5]
Herraiz I, Simón E, Gómez-Arriaga P, et al. Angiogenesis-related biomarkers (sFlt-1/PLGF) in the prediction and diagnosis of placental dysfunction: An approach for clinical integration. Int J Mol Sci 2015; 16(8): 19009-26.
[http://dx.doi.org/10.3390/ijms160819009] [PMID: 26287164]
[6]
Hansson SR, Nääv Å, Erlandsson L. Oxidative stress in preeclampsia and the role of free fetal hemoglobin. Front Physiol 2015; 5: 516.
[http://dx.doi.org/10.3389/fphys.2014.00516] [PMID: 25628568]
[7]
Bengal W, Bengal W. Application of cell-free fetal DNA for early evaluation of preeclampsia to reduce maternal mortality by low-cost method – A prospective cohort study. Indian J Biochem Biophys 2018; 55(10): 334-40.
[8]
Mazibuko M, Moodley J, Naicker T. Dysregulation of circulating sTie2 and sHER2 in HIV-infected women with preeclampsia. Hypertens Pregnancy 2019; 38(2): 89-95.
[http://dx.doi.org/10.1080/10641955.2019.1584211] [PMID: 30836796]
[9]
Phoswa WN, Naicker T, Ramsuran V, Moodley J. Pre-eclampsia: the role of highly active antiretroviral therapy and immune markers. Inflamm Res 2019; 68(1): 47-57.
[http://dx.doi.org/10.1007/s00011-018-1190-3] [PMID: 30276649]
[10]
Brown MA, Magee LA, Hall DR, et al. The 2021 International Society for the Study of Hypertesion in Pregnancy Classification, Diagnosis & Management Recommendations for International Practice. Pregnancy Hypertens. 2021 March; 27: 148-69.
[11]
Kulkarni AV, Mehendale SS, Yadav HR, Kilari AS, Taralekar VS, Joshi SR. Circulating angiogenic factors and their association with birth outcomes in preeclampsia. Hypertens Res 2010; 33(6): 561-7.
[http://dx.doi.org/10.1038/hr.2010.31] [PMID: 20224572]
[12]
Molvarec A, Szarka A, Walentin S, Szűcs E, Nagy B, Rigó J Jr. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertens Res 2010; 33(9): 892-8.
[http://dx.doi.org/10.1038/hr.2010.92] [PMID: 20535121]
[13]
Palmer KR, Tong S, Kaitu’u-Lino TJ. Placental-specific sFLT-1: role in pre-eclamptic pathophysiology and its translational possibilities for clinical prediction and diagnosis. Mol Hum Reprod 2017; 23(2): 69-78.
[PMID: 27986932]
[14]
Govender N, Naicker T, Moodley J. Maternal imbalance between proangiogenic and anti-angiogenic factors in HIV-infected women with preeclampsia: cardiovascular topics. Cardiovasc J Afr 2013; 24(5): 174-9.
[http://dx.doi.org/10.5830/CVJA-2013-029] [PMID: 24217170]
[15]
Naidoo N, Moodley J, Naicker T. Maternal endothelial dysfunction in HIV-associated preeclampsia comorbid with COVID-19: a review. Hypertens Res 2021; 44(4): 386-98.
[http://dx.doi.org/10.1038/s41440-020-00604-y] [PMID: 33469197]
[16]
Hoeller A, Ehrlich L, Golic M, et al. Placental expression of sFlt-1 and PlGF in early preeclampsia vs. early IUGR vs. age-matched healthy pregnancies. Hypertens Pregnancy 2017; 36(2): 151-60.
[http://dx.doi.org/10.1080/10641955.2016.1273363] [PMID: 28609172]
[17]
Powis KM, McElrath TF, Hughes MD, et al. High viral load and elevated angiogenic markers associated with increased risk of preeclampsia among women initiating highly active antiretroviral therapy in pregnancy in the Mma Bana study, Botswana. J Acquir Immune Defic Syndr 2013; 62(5): 517-24.
[http://dx.doi.org/10.1097/QAI.0b013e318286d77e] [PMID: 23344545]
[18]
Djeha A, Girard S, Trottier H, et al. No association between early antiretroviral therapy during pregnancy and plasma levels of angiogenic factors: a cohort study. BMC Pregnancy Childbirth 2019; 19(1): 482.
[http://dx.doi.org/10.1186/s12884-019-2600-4] [PMID: 31815612]
[19]
Pattinson RC, Moodley J. Saving Mothers 2014-2016: Seventh triennial report on confidential enquiries into maternal deaths in South Africa:Short report. Available from: https://www.westerncape.gov.za/assets/departments/health/saving_mothers_2014-16_-_short_report. pdf
[20]
Adams JW, Watts DH, Phelps BR. A systematic review of the effect of HIV infection and antiretroviral therapy on the risk of preeclampsia. Int J Gynaecol Obstet 2016; 133(1): 17-21.
[http://dx.doi.org/10.1016/j.ijgo.2015.08.007] [PMID: 26797203]
[21]
Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis 2012; 206(11): 1695-705.
[http://dx.doi.org/10.1093/infdis/jis553] [PMID: 23066160]
[22]
Wimalasundera RC, Larbalestier N, Smith JH, et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002; 360(9340): 1152-4.
[http://dx.doi.org/10.1016/S0140-6736(02)11195-0] [PMID: 12387967]
[23]
Shibuya M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer 2011; 2(12): 1097-105.
[http://dx.doi.org/10.1177/1947601911423031] [PMID: 22866201]
[24]
Wang K, Zheng J. Signaling regulation of fetoplacental angiogenesis. J Endocrinol 2012; 212(3): 243-55.
[http://dx.doi.org/10.1530/JOE-11-0296] [PMID: 22106098]
[25]
Chau K, Hennessy A, Makris A. Placental growth factor and preeclampsia. J Hum Hypertens 2017; 31(12): 782-6.
[http://dx.doi.org/10.1038/jhh.2017.61] [PMID: 29115294]
[26]
Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Science's STKE 2001; 2001(112): 21.
[27]
Fujisawa H. From the discovery of neuropilin to the determination of its adhesion sites. Adv Exp Med Biol 2002; 515: 1-12.
[http://dx.doi.org/10.1007/978-1-4615-0119-0_1] [PMID: 12613539]
[28]
Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380(6573): 439-42.
[http://dx.doi.org/10.1038/380439a0] [PMID: 8602242]
[29]
Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7(5): 575-83.
[http://dx.doi.org/10.1038/87904] [PMID: 11329059]
[30]
Gaiser R. Circulating angiogenic factors and the risk of preeclampsia. Surv Anesthesiol 2005; 49(1): 14-5.
[http://dx.doi.org/10.1097/01.sa.0000151206.53344.39]
[31]
Staff AC, Fjeldstad HE, Fosheim IK, et al. Failure of physiological transformation and spiral artery atherosis: their roles in preeclampsia. Am J Obstet Gynecol 2020; Feb 226(2S): S895-906.
[PMID: 32971013]
[32]
Nikuei P, Rajaei M, Roozbeh N, et al. Diagnostic accuracy of sFlt1/PlGF ratio as a marker for preeclampsia. BMC Pregnancy Childbirth 2020; 20(1): 80.
[http://dx.doi.org/10.1186/s12884-020-2744-2] [PMID: 32033594]
[33]
Huhn EA, Kreienbühl A, Hoffmann I, et al. Diagnostic accuracy of different soluble fms-like tyrosine Kinase 1 and placental growth factor cut-off values in the assessment of preterm and term preeclampsia: A gestational age matched case-control study. Front Med (Lausanne) 2018; 5(11): 325.
[http://dx.doi.org/10.3389/fmed.2018.00325] [PMID: 30560128]
[34]
Lapaire O, Shennan A, Stepan H. The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application. Eur J Obstet Gynecol Reprod Biol 2010; 151(2): 122-9.
[http://dx.doi.org/10.1016/j.ejogrb.2010.04.009] [PMID: 20457483]
[35]
Wang A, Rana S, Karumanchi SA. Preeclampsia: The role of angiogenic factors in its pathogenesis. Physiology 2009; 24(3): 147-58.
[http://dx.doi.org/10.1152/physiol.00043.2008]
[36]
Ajadi I, Maduray K, Eche S, Gathiram P, Mackraj I. Serum levels of vasoactive factors in HIV-infected pre-eclamptic women on HAART. J Obstet Gynaecol 2020; 0(0): 1-6.
[PMID: 32515639]
[37]
Nuzzo AM, Giuffrida D, Moretti L, et al. Placental and maternal sFlt1/PlGF expression in gestational diabetes mellitus. Sci Rep 2021; 11(1): 2312.
[http://dx.doi.org/10.1038/s41598-021-81785-5] [PMID: 33504861]
[38]
Kasdaglis T, Aberdeen G, Turan O, et al. Placental growth factor in the first trimester: relationship with maternal factors and placental Doppler studies. Ultrasound Obstet Gynecol 2010; 35(3): 280-5.
[http://dx.doi.org/10.1002/uog.7548] [PMID: 20052659]
[39]
Gu Y, Lewis DF, Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008; 93(1): 260-6.
[http://dx.doi.org/10.1210/jc.2007-1550] [PMID: 17956952]
[40]
Govender N, Moodley J, Gathiram P, Naicker T. Soluble fms-like tyrosine kinase-1 in HIV infected pre-eclamptic South African Black women. Placenta 2014; 35(8): 618-24.
[http://dx.doi.org/10.1016/j.placenta.2014.04.013] [PMID: 24880209]
[41]
Siemieniuk RAC, Lytvyn L, Mah Ming J, et al. Antiretroviral therapy in pregnant women living with HIV: a clinical practice guideline. BMJ 2017; 358: j3961.
[http://dx.doi.org/10.1136/bmj.j3961] [PMID: 28893728]
[42]
Giuliano M, Andreotti M, Liotta G, et al. Maternal antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Malawi: maternal and infant outcomes two years after delivery. PLoS One 2013; 8(7): e68950.
[http://dx.doi.org/10.1371/journal.pone.0068950] [PMID: 23894379]
[43]
Tai JH, Udoji MA, Barkanic G, et al. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. J Infect Dis 2007; 196(7): 1044-52.
[http://dx.doi.org/10.1086/520814] [PMID: 17763327]
[44]
Muthuka JK, Kombe Y, Makokha A, Kiptoo M. Risk factors for adverse pregnancy events and correlation with HIV immune reconstitution inflammatory response among women of reproductive age in selected hospitals, Nairobi, Kenya. East Afr Med J 2020; 97(11)
[45]
Duhig KE, Myers J, Seed PT, et al. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. Lancet 2019; 393(10183): 1807-18.
[http://dx.doi.org/10.1016/S0140-6736(18)33212-4] [PMID: 30948284]
[46]
Lopes Perdigao J, Chinthala S, Mueller A, et al. Angiogenic factor estimation as a warning sign of preeclampsiarelated peripartum morbidity among hospitalized patients. Hypertension 2019; 73(4): 868-77.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.118.12205] [PMID: 30798660]
[47]
Dröge LA, Perschel FH, Stütz N, et al. Prediction of preeclampsia-related adverse outcomes with the sflt-1 (soluble fms-like tyrosine kinase 1)/plgf (placental growth factor)-ratio in the clinical routine. Hypertension 2021; 77(2): 461-71.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.15146] [PMID: 33280406]